ClinicaliQ Trial Snapshot
- Mayo AVC Registry and Biobank — Recruiting • Cardiology / Cardiovascular • NCT03049254.
- What is being tested: A registry and biobank collecting clinical data and biological samples from patients with arrhythmogenic ventricular cardiomyopathy (AVC) to improve understanding of this genetic heart condition and its progression.
- Patient eligibility overview: Individuals diagnosed with AVC and their blood relatives who require screening, including those at risk of inheriting this genetic condition affecting the heart.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
Arrhythmogenic ventricular cardiomyopathy (AVC) is a genetic condition which affects the heart and can lead to heart failure and rhythm problems, of which, sudden cardiac arrest or death is the most tragic and dangerous. Diagnosis and screening of blood-relatives is very difficult as the disease process can be subtle, but sufficient enough, so that the first event is sudden death. The Mayo Clinic AVC Registry is a collaboration between Mayo Clinic, Rochester, USA and Papworth Hospital, Cambridge University Hospitals, Cambridge, UK. The investigators aim to enroll patients with a history…
Eligibility Snapshot
- : * Patients with a diagnosis of a non-MI SCA who survived * Patients with a non-MI SCD * Patient with a SCA associated with seizures, epilepsy, syncope, drowning and near-drowning, where a cardiomyopathy is suspected * Family member of a patient diagnosed with primary cardiomyopathy (including HCM, idiopathic DCM, AVC)
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.